Two academic teams have independently shown that targeting the inflammasome reduces retinal damage in mouse models of age-related macular degeneration. One study favors inhibiting inflammasome activation to treat dry AMD, and those findings are licensed to iVeena Pharmaceuticals. The other approach suggests boosting the inflammasome to treat wet AMD.